These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31392399)

  • 1. Evaluating RANKL and OPG levels in patients with Duchenne muscular dystrophy.
    Akhtar Ali S; Kang H; Olney R; Ramos-Platt L; Ryabets-Lienhard A; Cheung C; Georgia S; Pitukcheewanont P
    Osteoporos Int; 2019 Nov; 30(11):2283-2288. PubMed ID: 31392399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
    Tsentidis C; Gourgiotis D; Kossiva L; Doulgeraki A; Marmarinos A; Galli-Tsinopoulou A; Karavanaki K
    Osteoporos Int; 2016 Apr; 27(4):1631-1643. PubMed ID: 26588909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duchenne muscular dystrophy: RANK/RANKL/OPG (receptor activator of nuclear factor-kB/RANK ligand/osteoprotegerin) system and glucocorticoids.
    Atilano-Miguel S; Barbosa-Cortés L; Ortiz-Muñiz R
    Bol Med Hosp Infant Mex; 2022; 79(5):275-283. PubMed ID: 36264895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum RANKL, osteoprotegerin (OPG) and RANKL/OPG ratio in children with systemic lupus erythematosus.
    Ali R; Hammad A; El-Nahrery E; Hamdy N; Elhawary AK; Eid R
    Lupus; 2019 Sep; 28(10):1233-1242. PubMed ID: 31403902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RANKL and OPG gene polymorphisms: associations with vertebral fractures and bone mineral density in premenopausal systemic lupus erythematosus.
    Bonfá AC; Seguro LP; Caparbo V; Bonfá E; Pereira RM
    Osteoporos Int; 2015 May; 26(5):1563-71. PubMed ID: 25609157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
    Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
    Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantifying RANKL and OPG levels in healthy children: A large cross-sectional analysis.
    Akhtar Ali S; Kang H; Olney R; Ramos-Platt L; Ryabets-Lienhard A; Georgia S; Pitukcheewanont P
    Bone; 2019 Oct; 127():215-219. PubMed ID: 31212033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of recent spinal cord injury on the OPG/RANKL system and its relationship with bone loss and the response to denosumab therapy.
    Gifre L; Ruiz-Gaspà S; Carrasco JL; Portell E; Vidal J; Muxi A; Monegal A; Guañabens N; Peris P
    Osteoporos Int; 2017 Sep; 28(9):2707-2715. PubMed ID: 28580511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy.
    Tian C; Wong BL; Hornung L; Khoury JC; Miller L; Bange J; Rybalsky I; Rutter MM
    Neuromuscul Disord; 2016 Nov; 26(11):760-767. PubMed ID: 27614576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RANKL:osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis.
    Rouster-Stevens KA; Langman CB; Price HE; Seshadri R; Shore RM; Abbott K; Pachman LM
    Arthritis Rheum; 2007 Mar; 56(3):977-83. PubMed ID: 17328075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
    Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
    Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in serum levels of TNF-alpha, IL-6, OPG, RANKL and their correlation with radiographic and clinical assessment in fragility fractures and high energy fractures.
    Giganti MG; Liuni F; Celi M; Gasbarra E; Zenobi R; Tresoldi I; Modesti A; Bei R; Tarantino U
    J Biol Regul Homeost Agents; 2012; 26(4):671-80. PubMed ID: 23241117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major.
    Pietrapertosa AC; Minenna G; Colella SM; Santeramo TM; Renni R; D'Amore M
    Panminerva Med; 2009 Mar; 51(1):17-23. PubMed ID: 19352306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease.
    Monegal A; Navasa M; Peris P; Alvarez L; Pons F; Rodés J; Guañabens N
    Liver Int; 2007 May; 27(4):492-7. PubMed ID: 17403189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women.
    Mezquita-Raya P; de la Higuera M; García DF; Alonso G; Ruiz-Requena ME; de Dios Luna J; Escobar-Jiménez F; Muñoz-Torres M
    Osteoporos Int; 2005 Nov; 16(11):1368-74. PubMed ID: 15711777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors associated with prevalent vertebral fractures in Duchenne muscular dystrophy.
    Phung K; McAdam L; Ma J; McMillan HJ; Jackowski S; Scharke M; Matzinger MA; Shenouda N; Koujok K; Jaremko JL; Smit K; Walker S; Hartigan C; Khan N; Konji VN; MacLeay L; Page M; Sykes E; Robinson ME; Alos N; Cummings EA; Ho J; Sbrocchi AM; Stein R; Saleh D; Craven BC; Dang UJ; Siminoski K; Rauch F; Ward LM
    Osteoporos Int; 2023 Jan; 34(1):147-160. PubMed ID: 36342539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone microarchitectural alterations in boys with Duchenne muscular dystrophy on long-term glucocorticoid treatment.
    Tung JY; Lam TP; Chan SH
    J Bone Miner Metab; 2021 Jul; 39(4):606-611. PubMed ID: 33400004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disturbance of the OPG/RANK/RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis.
    Bai P; Sun Y; Jin J; Hou J; Li R; Zhang Q; Wang Y
    Respir Res; 2011 Dec; 12(1):157. PubMed ID: 22176920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the Muscle-Bone Unit: Filling Two Needs with One Deed in the Treatment of Duchenne Muscular Dystrophy.
    Boulanger Piette A; Hamoudi D; Marcadet L; Morin F; Argaw A; Ward L; Frenette J
    Curr Osteoporos Rep; 2018 Oct; 16(5):541-553. PubMed ID: 30225627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between low bone mass and the serum RANKL and OPG in patients with nephrolithiasis.
    Mansour A; Aboeerad M; Qorbani M; Hashemi Taheri AP; Pajouhi M; Keshtkar AA; Larijani B; Mohajeri-Tehrani MR; Ganji MR
    BMC Nephrol; 2018 Jul; 19(1):172. PubMed ID: 29996796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.